Anti-LFA-1 improves pig islet xenograft function in diabetic mice when long-term acceptance is induced by CTLA4Ig/anti-CD40L

Transplantation. 2007 May 15;83(9):1259-67. doi: 10.1097/01.tp.0000261722.02697.75.

Abstract

Background: It has been previously demonstrated that addition of anti-LFA-1 to a combination of CTLA4Ig and anti-CD40L induces the permanent acceptance of dopaminergic fetal pig xenografts when transplanted into the brain of wild-type mice. The purpose of this study was to test whether this costimulation blockade also can induce acceptance of adult pig islets transplanted to C57BL/6 mice with streptozotocin-induced diabetes.

Methods: Recipients were treated with CTLA4Ig/anti-CD40L+/-anti-LFA-1 or isotype control antibodies during the first week after transplantation. Half of the costimulation blockade-treated recipients had their grafts removed after 8 weeks. The other half was observed up to 5 months.

Results: Recipients treated with CTLA4Ig/anti-CD40L/anti-LFA-1 had significantly lower blood glucose and gained more weight than CTLA4Ig/anti-CD40L-treated recipients. CTLA4Ig/anti-CD40L-treated recipients exhibited unstable blood glucose. IPGTT of these recipients revealed a slow recovery to normal blood glucose levels at week 4. In comparison, CTLA4Ig/anti-CD40L/anti-LFA-1 treated recipients exhibited a significantly superior glucose clearance. CTLA4Ig/anti-CD40L+/-anti-LFA-1 treated recipients did not produce anti-pig IgG, whereas control antibody-treated mice did. CD4+ T cells from costimulation blockade-treated recipients proliferated less than CD4+ T cells from control antibody-treated mice when co-cultured with syngeneic antigen presenting cells loaded with pig islet antigens.

Conclusions: CTLA4Ig/anti-CD40L/anti-LFA-1-treated recipients had superior islet function compared with CTLA4Ig/anti-CD40L-treated recipients. However, both costimulation blockade regimens led to islet graft acceptance up to 5 months after a 1-week treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abatacept
  • Animals
  • Antibodies / pharmacology*
  • Blood Glucose / metabolism
  • CD4-Positive T-Lymphocytes / immunology
  • CD4-Positive T-Lymphocytes / pathology
  • CD40 Ligand / immunology*
  • Cell Proliferation
  • Diabetes Mellitus, Experimental / blood
  • Diabetes Mellitus, Experimental / surgery*
  • Epitopes
  • Female
  • Glucose / pharmacology
  • Immunoconjugates / pharmacology*
  • Immunoglobulin G / biosynthesis
  • Immunoglobulin G / immunology
  • Islets of Langerhans / drug effects
  • Islets of Langerhans / pathology
  • Islets of Langerhans / physiopathology*
  • Islets of Langerhans Transplantation*
  • Leukocytes / pathology
  • Lymphocyte Function-Associated Antigen-1 / immunology*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Nude
  • Swine
  • Time Factors
  • Transplantation, Heterologous*

Substances

  • Antibodies
  • Blood Glucose
  • Epitopes
  • Immunoconjugates
  • Immunoglobulin G
  • Lymphocyte Function-Associated Antigen-1
  • CD40 Ligand
  • Abatacept
  • Glucose